Pancreatic Cancer Causes: Several Diabetic Drugs Have Been Shown to Cause An Increased Risk of Pancreatic Cancer by Pancreatic Cancer Lawyer Jason S. Coomer

 Pancreatic Cancer Causes: Several Different Types of Diabetes Drugs Have Been Shown To Cause An Increased Risk of Pancreatic Cancer by Pancreatic Cancer Lawyer Jason S. Coomer

Recent scientific studies have shown that several diabetes drugs may cause an increased risk of pancreatic cancer.  People that are taking Onglyza, Tradjenta, Bydureon, Oseni, Byetta, Victoza, Januvia, or Janumet should be aware of the potential dangers of these drugs and should discuss the potential dangers of these drugs with their physician.  

If you have lost a loved one from Pancreatic Cancer who was taking a diabetes drug or you have been taking a diabetes drug and have been diagnosed with Pancreatic Cancer, please report the adverse action to the prescribing medical doctor and FDA as soon as possible.  Attorneys are in the process of filing and reviewing lawsuits where a person has developed pancreatic cancer after taking Onglyza, Tradjenta, Bydureon, Oseni, Byetta, Victoza, Januvia, and/or Janumet. For more information on this topic, please feel free to contact Pancreatic Cancer Lawyer, Jason S. Coomer or go to the following webpage: Pancreatic Cancer Lawsuit Information.

Pancreatic Cancer Detection: Understanding and Identifying Symptoms of Pancreatic Cancer Can Be Important In Early Detection and Treatment of Pancreatic Cancer Resulting in Higher Pancreatic Cancer Survival Rates

Symptoms of pancreatic cancer can include: dark urine and clay-colored stools, fatigue and weakness, jaundice (a yellow color in the skin, mucus membranes, or eyes), loss of appetite and weight loss, nausea and vomiting, pain or discomfort in the upper part of the belly or abdomen, back pain, blood clots, diarrhea, and indigestion.

Pancreatic cancer is often not detected early on and is often advanced when it is first found.  As such, ninety-five percent of the people diagnosed with this cancer will not be alive 5 years later.  Some patients have pancreatic cancer that can be surgically removed are cured. However, in more than 80% of patients the tumor has already spread and cannot be completely removed at the time of diagnosis.  In the few cases where pancreatic tumors can be removed by surgery. The standard surgical procedure to remove pancreatic tumors is called a Whipple procedure (pancreatoduodenectomy or pancreaticoduodenectomy). This surgery should be done by an experienced surgeon and at a medical center that performs the procedure often. Some studies suggest that the Whipple procedure is best performed at hospitals that do more than five of these surgeries per year.

When the tumor has not spread out of the pancreas, but cannot be removed, radiation therapy and chemotherapy together may be recommended. When the tumor has spread (metastasized) to other organs such as the liver, chemotherapy alone is usually used. The standard chemotherapy drug is gemcitabine, but other drugs may be used. Gemcitabine can help about 25% of patients.

Patients whose tumor cannot be totally removed, but who have a blockage of the tubes that transport bile (biliary obstruction) must have that blockage relieved. There are two approaches including surgery and placement of a tiny metal tube (biliary stent) during ERCP.

Managing pain and other symptoms is an important part of treating advanced pancreatic cancer. Palliative care tams and hospice can help with pain and symptom management, and provide psychological support for patients and their families during the illness.

The Diabetes Drug Market is Over $40 Billion Each Year and Growing Rapidly Encouraging Drug Companies To Push Dangerous Diabetes Drugs For Profits

More than 300 million people worldwide suffer from diabetes, including about 30 million Americans.  In 2010, the global prevalence of diabetes was estimated to have reached 285 million and predicted to reach 438 million by 2030. The corresponding figures for North America were 37.4 million in 2010 and 53.2 million by 2030 and in Europe 55.2 million in 2010 and 66.2 million in 2030.  The global market for products in the management of diabetes currently stands at $41 billion and is on pace to grow to over $114 billion by 2018.